Over the past two decades, high-performance computing (HPC) has become widely used throughout drug discovery and development. Significant advances in HPC processing power in the early 2000s made it viable for tasks like reverse-engineering models of human disease progression and drug response or processing vast amounts of data from sources like the Human Genome Project. An article published in Expert Opinion on Drug Discovery claimed, “we can safely state that it would not be possible to process all the information available in the chemical databases of potential drug compounds, either accurately or quickly without HPC, since the required computational power is huge.”
One aspect of this shift that often goes overlooked is the new demands that HPC workloads place on IT and network operations (NetOps) teams at the organizations that use them. High-performance computing re…